<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) belong to the most frequent <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow diseases</z:e> with a crude incidence of about 4 in 100,000 per year </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> still is mainly based on morphologic findings in blood and marrow </plain></SENT>
<SENT sid="2" pm="."><plain>The new WHO classification system takes into account the medullary and peripheral blast count as well as the degree of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in the different cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>To correctly identify <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> types, cytogenetic evaluation is of importance, as the WHO classification introduced the entity <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with del(5q), which is characterized by special morphologic and hematologic features </plain></SENT>
<SENT sid="4" pm="."><plain>The separation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> has been redefined using a cutoff value of 20% peripheral and/or medullary blasts </plain></SENT>
<SENT sid="5" pm="."><plain>The International Prognostic Scoring System still is the gold standard in prognostication, but new items like transfusion need will be used more and more and have been incorporated into the WHO adapted Prognostic Scoring System </plain></SENT>
<SENT sid="6" pm="."><plain>In childhood, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is uncommon, accounting for less than 5% of <z:hpo ids='HP_0000001'>all</z:hpo> hematopoietic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in patients less than 14 years of age </plain></SENT>
<SENT sid="7" pm="."><plain>To accommodate for the characteristics of pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, a simple classification scheme based on morphological features and conforming with the WHO suggestions was proposed </plain></SENT>
<SENT sid="8" pm="."><plain>The dysplastic prodrome of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> in <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> is classified within myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> in <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> and excluded from the population-based studies of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>